Konruns Doses First Patient in Phase 2 Esophageal Cancer Trial for KC1036
Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced first patient dosing in the Phase 2 KC1036‑COM‑01...
Fineline Cube
Johnson & Johnson’s TECVAYLI Gets FDA Priority Review for Myeloma Combo
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA selected the teclistamab MajesTEC‑3 supplemental...
uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials
uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next‑generation...
Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option
Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop...
Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non‑exclusive agreements with Pfizer Inc. (NYSE: PFE) to...
Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
GSK’s Nucala Wins CHMP Nod for COPD in Europe
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...
Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...
Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...
Innovent’s Mazdutide Wins Macau Approval for Weight Management
Innovent Biologics, Inc. (HKG: 1801) announced that mazdutide received marketing approval from Macau’s drug regulatory...
Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study
Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...
China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028
The National Healthcare Security Administration (NHSA) released a notice to optimize healthcare fund settlement management,...
Junshi Biosciences Wins FDA Nod for EGFR/HER3 Bispecific ADC in Solid Tumors
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and...
Henlius Serplulimab NDA Wins Priority Review for Gastric Cancer as Adjuvant Therapy
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the NMPA accepted its New Drug Application...
Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. released its prospectus for a Hong Kong Stock Exchange listing...
China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027
China’s National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Administration of Traditional Chinese...
Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...
Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market
Suzhou Huadao Biological Pharmacy Co., Ltd. officially submitted a Marketing Authorization Application (MAA) to the...